Inhibrx Biosciences, Inc. (INXB)
Inhibrx Biosciences, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in La Jolla, CA, US. The stock last traded at $15.86, up 13.94% on the session, giving a market capitalisation of $225.9M. On trailing twelve-month figures it carries a trailing P/E of -11.49, a net margin of -10014.2%. Its beta of 2.88 implies it has historically moved more than the broad market.
Inhibrx Biosciences, Inc. operates as a clinical-stage biopharmaceutical entity, primarily focused on developing advanced biologic treatments for critical, life-threatening medical conditions. Key assets within its development pipeline include: INBRX-109, a tetravalent investigational therapy, is progressing through Phase 2 clinical trials. It is specifically engineered to target death-receptor 5 for the management of advanced, unresectable, or metastatic conventional chondrosarcoma. INBRX-106, a hexavalent sdAb-based investigational treatment targeting OX4, is also in Phase 2 clinical development. This candidate is being evaluated for its potential to treat a diverse array of metastatic solid tumors, encompassing non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancers, renal cell carcinoma, and urothelial (transitional) cell carcinoma. Established in 2024, Inhibrx Biosciences maintains its headquarters in La Jolla, California.
Inhibrx Biosciences, Inc. is most often compared with the following Healthcare names: